[go: up one dir, main page]

WO1994012030A1 - Composition injectable - Google Patents

Composition injectable Download PDF

Info

Publication number
WO1994012030A1
WO1994012030A1 PCT/US1993/011199 US9311199W WO9412030A1 WO 1994012030 A1 WO1994012030 A1 WO 1994012030A1 US 9311199 W US9311199 W US 9311199W WO 9412030 A1 WO9412030 A1 WO 9412030A1
Authority
WO
WIPO (PCT)
Prior art keywords
taxol
solution
acid
composition
castor oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/011199
Other languages
English (en)
Inventor
David R. Carver
Timothy R. Prout
Hernita Ewald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tapestry Pharmaceuticals Inc
Original Assignee
Tapestry Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994012030(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tapestry Pharmaceuticals Inc filed Critical Tapestry Pharmaceuticals Inc
Priority to AU56126/94A priority Critical patent/AU5612694A/en
Publication of WO1994012030A1 publication Critical patent/WO1994012030A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Definitions

  • This invention relates to a solution of taxol having improved stability.
  • Taxol is a compound extracted from the bark of a western yew, Taxus brevifolia and known for its antineoplastic activity. It is described for example in The Merck Index, Eleventh Edition 1989, monograph 9049.
  • taxol was chosen for development as an antineoplastic agent because of its unique mechanism of action and good cytotoxic activity against IP implanted D16 melanoma and the human X-l mammary tumor xenograft.
  • Taxol is believed to function as a mitotic spindle poison and as a potent inhibitor of cell replication in vitro. Other mitotic spindle points (colchicine and podophyllotoxin) inhibit microtubule assembly. Taxol employs a different mechanism of action since it appears to shift the equilibrium of polymerimization/depolymerization toward polymer assembly and to stabilize microtubules against depolymerization under conditions which would cause rapid disaggregation of microtubules. The interference with the polymerization/depolymerization cycle in cells appears to interfere with both the replication and migration of cells.
  • taxol After extensive preclinical screening in mouse tumor models, taxol entered clinical trials in 1983. Over the past few years, taxol has demonstrated good response rates in treating both ovarian and breast cancer patients who were not benefiting from vinca alkaloid or cisplatin therapy. It has also shown encouraging results in patients with other types of cancer including lung, melanoma, lymphoma, head and neck.
  • the invention provides a solution containing taxol, cremophor EL TM and ethanol, characterized in that the pH of the solution has been adjusted into the range 1 to 8 by addition of an acid.
  • Acids in the form of powders for example citric acid, are preferred over those which contain water, for example sulfuric acid.
  • the most preferred acid for use in accordance with the present invention is citric acid but a wide range of acids may be used including the following:
  • Taxol Due to its limited solubility in water, Taxol is usually prepared and administered in a vehicle containing cremophor EL
  • TM a polyethoxylated castor oil which acts as a solubilizer
  • ethanol a commercially available solution supplied by Bristol- Myers Squibb (BMS) is formulated with these components and has a pH of 9.1.
  • the invention essentially teaches addition of an acid to a taxol formulation to adjust its pH into the range 1 to 8, preferable 5 to 7.
  • Citric acid was dissolved in absolute alcohol, using a ratio of 8 mis of absolute alcohol to 1 gram of citric acid, and the solution was stirred for fifteen (15) minutes.
  • SOLUTION 2
  • Cremophor EL was weighed out into the main mixing vessel. SOLUTION 3
  • Solution 1 was added to solution 2, and the container used for solution 2 was washed with a minimum quantity of absolute alcohol to ensure complete transfer of the citric acid.
  • Solution 3 was mixed and bubbled with nitrogen for at least 15 minutes.
  • the taxol was weighed out and slurried using absolute alcohol, using a ratio of 8 ml of absolute alcohol to 1 gm of taxol.
  • the slurried taxol was added to solution 3 and the slurrying vessel was washed with a minimum quantity of absolute alcohol.
  • Solution 3 was adjusted to 75% of required volume using absolute alcohol, and thoroughly stirred for at least 45 minutes until completely dissolved. Once completely dissolved, the volume was checked and made up as necessary with absolute alcohol and the final solution stirred for 5 minutes.
  • Example 1 Example 1
  • the solutions were filled into clear type 1 glass 5 mL vials and sealed with rubber bungs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Une composition de taxol et d'huile de ricin polyéthoxylée est équilibrée par rapport au pH, de façon à présenter un pH inférieur à 8,1, afin d'en améliorer la stabilité. Cette composition peut comprendre un acide, de préférence l'acide citrique, permettant d'ajuster la valeur du pH. L'invention se rapporte également à un procédé de formulation d'une solution de taxol destinée à être injectée, et consistant à mélanger un acide avec une substance formant un excipient, telle que l'huile de ricin, pour former un excipient en solution, après quoi le taxol est mélangé avec ladite solution pour former la solution de taxol présentant un pH inférieur à 8,1.
PCT/US1993/011199 1992-11-27 1993-11-18 Composition injectable Ceased WO1994012030A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56126/94A AU5612694A (en) 1992-11-27 1993-11-18 Injectable composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPL6074 1992-11-27
AUPL607492 1992-11-27
US99550192A 1992-12-22 1992-12-22
US07/995,501 1992-12-22

Publications (1)

Publication Number Publication Date
WO1994012030A1 true WO1994012030A1 (fr) 1994-06-09

Family

ID=25644377

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1993/011199 Ceased WO1994012030A1 (fr) 1992-11-27 1993-11-18 Composition injectable
PCT/US1993/011209 Ceased WO1994012031A1 (fr) 1992-11-27 1993-11-18 Composition injectable

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011209 Ceased WO1994012031A1 (fr) 1992-11-27 1993-11-18 Composition injectable

Country Status (12)

Country Link
US (7) US5733888A (fr)
EP (4) EP0674510B1 (fr)
JP (1) JP2880292B2 (fr)
AT (2) ATE169216T1 (fr)
AU (1) AU5612694A (fr)
CA (2) CA2149150C (fr)
DE (2) DE69320206T2 (fr)
DK (2) DK0835657T3 (fr)
ES (2) ES2119996T3 (fr)
GR (1) GR3027724T3 (fr)
PT (1) PT835657E (fr)
WO (2) WO1994012030A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710534A1 (fr) * 1994-09-28 1995-04-07 Bristol Myers Squibb Co Solvant de stabilisation, composition pharmaceutique le contenant, et son procédé de préparation.
EP0645145A3 (fr) * 1993-09-29 1995-05-24 Bristol Myers Squibb Co Composition pharmaceutique stabilisée et solvant stabilisant.
EP0674510A4 (fr) * 1992-11-27 1995-08-12 Napro Biotherapeutics Inc Composition injectable.
WO1998057630A1 (fr) * 1997-06-13 1998-12-23 Laboratoires Thissen (L.T.B.) Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition
EP0876145A4 (fr) * 1995-12-21 1999-04-21 Genelabs Tech Inc Composition de taxane et procede s'y rapportant
US6096911A (en) * 1995-09-28 2000-08-01 Basf Aktiengesellschaft Process for purifying alkoxylated fats
JP2005534656A (ja) * 2002-06-10 2005-11-17 プリヴァ−ラチェマ アー．エス． ポリオキシエチル化ひまし油に基づく安定化医薬組成物およびその製造方法
WO2014140213A1 (fr) 2013-03-14 2014-09-18 Pharmachemie B.V. Principe de purification de taxoïde pour des excipients liquides

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
CA2347097C (fr) 1998-10-20 2009-06-16 Ben Venue Laboratories, Inc. Procede de purification de solvants s'utilisant pour la preparation de compositions pharmaceutiques
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
CN1361760A (zh) 1999-05-14 2002-07-31 尼瑞斯药品公司 新的白介素－1和肿瘤坏死因子－α调节剂、所述调节剂的合成以及使用所述调节剂的方法
DE19925211B4 (de) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit zur Herstellung einer Formulierung von Paclitaxel
JP2003520230A (ja) * 2000-01-20 2003-07-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 活性炭を用いたポリオキシエチル化ヒマシ油の精製およびこれの医薬組成物
JP2003521545A (ja) * 2000-02-02 2003-07-15 フロリダ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッド 改良された溶解性を有するタキサン製剤
DE60139544D1 (de) * 2000-02-23 2009-09-24 Life Technologies Corp Veränderte, fluoreszierende proteine
US6951885B2 (en) 2000-08-10 2005-10-04 Takeda Pharmaceutical Company Limited Pharmaceutical composition
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
EP1341414B1 (fr) * 2000-11-16 2013-01-02 The Regents of The University of California Taxon d'actinomycete marin utilise pour la decouverte de medicaments et de produits de fermentation
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7141251B2 (en) 2001-04-06 2006-11-28 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
CA2466851C (fr) * 2001-11-26 2012-09-11 Supergen, Inc. Procede de preparation et d'utilisation d'huile de ricin polyoxyethylee dans des compositions pharmaceutiques
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
KR20040066921A (ko) * 2001-12-20 2004-07-27 브리스톨-마이어스스퀴브컴파니 생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
ES2295695T3 (es) * 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
EP1606065A4 (fr) * 2003-02-11 2010-09-29 Univ Northwestern Procedes et matieres pour revetements de surface nanocristallins et liaison de nanofibres d'amphiphiles peptidiques sur ceux-ci
US20050049294A1 (en) * 2003-06-20 2005-03-03 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CN101791306A (zh) * 2003-06-20 2010-08-04 加利福尼亚大学董事会 盐孢菌酰胺及其使用方法
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (fr) * 2003-07-29 2005-01-29 Invitrogen Corporation Tests de kinase et de phosphatase
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
PT1694660E (pt) * 2003-12-12 2009-07-16 Quiral Quimica Do Brasil Processo de preparação de ingredientes farmacêuticos activos (api) anidros e hidratados; composições farmacêuticas estáveis preparadas a partir dos mesmos e utilizações das referidas composições
WO2005070922A2 (fr) * 2004-01-23 2005-08-04 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles utiles en tant qu'agents antimicrobiens
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP2007535559A (ja) * 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
WO2006060676A1 (fr) 2004-12-03 2006-06-08 Dana Farber Cancer Institute Compositions et procedes destines au traitement des maladies neoplastiques
KR20060121721A (ko) * 2005-05-23 2006-11-29 주식회사 중외제약 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물
WO2006133510A1 (fr) * 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Compositions pharmaceutiques liquides de docétaxel
US7893299B2 (en) 2005-07-21 2011-02-22 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-αmodulators; syntheses of such modulators and methods of using such modulators
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
ES2784794T3 (es) * 2005-08-31 2020-10-01 Abraxis Bioscience Llc Composiciones que comprenden agentes farmacéuticos poco solubles en agua y agentes antimicrobianos
CN100548274C (zh) * 2006-01-12 2009-10-14 永信药品工业股份有限公司 紫杉醇水性注射液及其制备方法
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
FR2912745A1 (fr) * 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
BRPI0912234A2 (pt) * 2008-05-12 2015-10-06 Nereus Pharmaceuticals Inc derivados de salinosporamida como inibidores de proteassomas
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) * 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
WO2011139899A2 (fr) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Formulations non aqueuses de pro-émulsions à base de taxane et procédés de fabrication et d'utilisation de ces formulations
MX342324B (es) 2011-03-29 2016-09-23 Sanofi Sa Formulaciones de otamixaban con estabilidad mejorada.
US20140234345A1 (en) * 2011-07-11 2014-08-21 Biolyse Pharma Corporation Novel anti-cancer isocarbostyril alkaloid conjugates
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2968390A4 (fr) * 2013-03-15 2016-10-26 Epizyme Inc Formulations injectables permettant de traiter le cancer
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
JP2017527614A (ja) 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
JP2017527567A (ja) * 2014-09-17 2017-09-21 エピザイム インコーポレイテッド 癌の治療のための注射製剤
CA2963923A1 (fr) 2014-10-08 2016-04-14 Pacific Northwest Research Institute Methodes et composes pour accroitre la puissance des agents antifongiques
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
MY194341A (en) 2015-03-06 2022-11-29 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
IL260933B2 (en) 2016-02-08 2023-04-01 Beyondspring Pharmaceuticals Inc Preparations containing tocorsol or its analogues
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
KR20190015361A (ko) 2016-06-06 2019-02-13 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
WO2018144764A1 (fr) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Méthode de réduction de la neutropénie
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
EP3743074A4 (fr) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. Composition et procédé pour réduire la thrombocytopénie par l'administration de plinabuline
MX2020010036A (es) 2018-03-28 2021-03-02 Herbalife Int Of America Inc Acetilacion de polisacaridos.
US11439586B2 (en) * 2018-10-16 2022-09-13 US Nano Food & Drug INC Intratumour injection formulation
EP4135686A4 (fr) 2020-04-13 2025-03-12 US Nano Food & Drug Inc Formulation d'injection intratumorale chimiothérapeutique basique
CA3215047A1 (fr) 2021-04-09 2022-10-13 Lan Huang Compositions therapeutiques et methodes de traitement de tumeurs
WO2024173418A1 (fr) 2023-02-16 2024-08-22 Infinitum Health, Llc Procédés d'inhibition de la croissance du cancer et d'inhibition d'infections virales

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552421B2 (fr) * 1971-08-06 1980-01-19
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
EP0468044B1 (fr) * 1990-02-15 1995-10-11 PQ Corporation Procede de traitement de l'huile de friture utilisant une composition d'alumine et de silice amorphe
TW223634B (fr) * 1991-03-18 1994-05-11 Kingston David G I
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
KR100371062B1 (ko) * 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 안정성이향상된주사가능한택솔조성물및이를제형화하는방법
ES2119996T3 (es) * 1992-11-27 1998-10-16 Napro Biotherapeutics Inc Composicion inyectable que comprende faclitaxel.
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5733388A (en) 1994-08-11 1998-03-31 Daido Tokiushuko Kabushiki Kaisha Steel composition for bearings and method of producing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835657A1 (fr) * 1992-11-27 1998-04-15 Napro Biotherapeutics, Inc. Composition injectable
EP1500393A1 (fr) * 1992-11-27 2005-01-26 Mayne Pharma (USA) Inc. Composition injectable de taxol
EP0674510A4 (fr) * 1992-11-27 1995-08-12 Napro Biotherapeutics Inc Composition injectable.
EP1384474A1 (fr) * 1992-11-27 2004-01-28 Napro Biotherapeutics, Inc. Composition injectable de taxol
BE1007987A5 (fr) * 1993-09-29 1995-12-05 Bristol Myers Squibb Co Composition pharmaceutique stabilisee et solvant stabilisant.
EP0645145A3 (fr) * 1993-09-29 1995-05-24 Bristol Myers Squibb Co Composition pharmaceutique stabilisée et solvant stabilisant.
FR2710534A1 (fr) * 1994-09-28 1995-04-07 Bristol Myers Squibb Co Solvant de stabilisation, composition pharmaceutique le contenant, et son procédé de préparation.
US6096911A (en) * 1995-09-28 2000-08-01 Basf Aktiengesellschaft Process for purifying alkoxylated fats
EP0876145A4 (fr) * 1995-12-21 1999-04-21 Genelabs Tech Inc Composition de taxane et procede s'y rapportant
WO1998057630A1 (fr) * 1997-06-13 1998-12-23 Laboratoires Thissen (L.T.B.) Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
JP2005534656A (ja) * 2002-06-10 2005-11-17 プリヴァ−ラチェマ アー．エス． ポリオキシエチル化ひまし油に基づく安定化医薬組成物およびその製造方法
WO2014140213A1 (fr) 2013-03-14 2014-09-18 Pharmachemie B.V. Principe de purification de taxoïde pour des excipients liquides

Also Published As

Publication number Publication date
CA2308082A1 (fr) 1994-06-09
JP2880292B2 (ja) 1999-04-05
DE69333605T2 (de) 2005-02-03
CA2149150A1 (fr) 1994-06-09
CA2149150C (fr) 2000-08-01
EP0674510A1 (fr) 1995-10-04
DE69320206T2 (de) 1999-02-11
ES2224200T3 (es) 2005-03-01
ES2119996T3 (es) 1998-10-16
DE69320206D1 (de) 1998-09-10
US20040204479A1 (en) 2004-10-14
US6306894B1 (en) 2001-10-23
US5972992A (en) 1999-10-26
ATE169216T1 (de) 1998-08-15
DE69333605D1 (de) 2004-09-30
EP0835657A1 (fr) 1998-04-15
US6140359A (en) 2000-10-31
PT835657E (pt) 2004-11-30
EP0835657B1 (fr) 2004-08-25
EP1500393A1 (fr) 2005-01-26
DK0674510T3 (da) 1999-05-10
US5733888A (en) 1998-03-31
US20030065022A1 (en) 2003-04-03
EP0674510A4 (fr) 1995-08-12
GR3027724T3 (en) 1998-11-30
EP1384474A1 (fr) 2004-01-28
AU5612694A (en) 1994-06-22
EP0674510B1 (fr) 1998-08-05
US6770670B2 (en) 2004-08-03
JPH08503945A (ja) 1996-04-30
DK0835657T3 (da) 2005-01-10
ATE274347T1 (de) 2004-09-15
WO1994012031A1 (fr) 1994-06-09
US5977164A (en) 1999-11-02

Similar Documents

Publication Publication Date Title
US5972992A (en) Injectable composition
WO1994012198A1 (fr) Composition a base de taxol injectable
US5438072A (en) Taxoid-based compositions
HU217839B (hu) Eljárások taxánszármazékokat tartalmazó új stabil gyógyszerkészítmények előállítására
CA1176567A (fr) Produit pharmaceutique
KR20080030024A (ko) 도세탁셀의 약제학적 액상제제
JP2003526612A (ja) タキソイド抗新生物薬を含有する安定化した注射可能な医薬組成物
FI69753B (fi) Foerfarande foer framstaellning av en salva pao basis av isosorbiddinitrat
AU2007246077A1 (en) Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
KR980008219A (ko) 안정화된 주사제용 약제학적 조성물
JP3748912B2 (ja) オーレオバシジン類の高濃度溶液製剤
JP2013194009A (ja) ドセタキセル製剤
JP2016216504A (ja) ドセタキセル製剤
US20070082945A1 (en) Discodermolide compositions
JP2018115178A (ja) ドセタキセル製剤
GB2388025A (en) Kit for preparing a formulation of paclitaxel
HK1106923B (en) Paclitaxel aqueous injection solution and methods for preparing the same
HK1106923A1 (zh) 紫杉醇水性注射液及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ RO RU SD SK UA UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase